Edwards Lifesciences Corporation
Financials
Valuation Metrics
Edwards Lifesciences Corporation's Market Cap is $51.15B. At end of 2025 it was $49.48B. Ranked #319 of 3,112 in US market (top 10%), #232 of 1,667 on NYSE (top 14%), #16 of 206 in Health Care Equipment & Services (top 8%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $51.15B | US#319/3,112 Sec#16/206 |
| Revenue | $6.30B | US#780/3,112 Sec#42/206 |
| Net Income | $1.09B | US#489/3,112 Sec#27/206 |
| Total Assets | $13.32B | US#813/3,112 Sec#38/206 |
| Net Assets | $10.33B | US#413/3,112 Sec#23/206 |
| Employees | 16,000 | US#433/3,112 Sec#41/206 |
| Value | ||
| P/E | 46.80x | US#1,806/3,112 Sec#90/206 |
| P/B | 4.95x | US#2,168/3,112 Sec#139/206 |
| PEG | 7.38x | US#1,249/3,112 Sec#62/206 |
| P/S | 8.11x | US#2,578/3,112 Sec#180/206 |
| EV/EBITDA | 34.77x | US#2,239/3,112 Sec#120/206 |
| FCF Yield | 2.13% | US#1,931/3,112 Sec#120/206 |
| Profitability | ||
| ROE | 10.58% | US#1,298/3,112 Sec#62/206 |
| ROA | 8.20% | US#597/3,112 Sec#35/206 |
| Op. Margin | 27.62% | US#539/3,112 Sec#17/206 |
| Revenue Growth | 16.70% | US#890/3,112 Sec#57/206 |
| Earnings Growth | 6.34% | US#1,241/3,112 Sec#63/206 |
| Financial Health | ||
| Debt Ratio | 28.99% | US#322/3,112 Sec#36/206 |
| Total Debt | $703M | US#1,650/3,112 Sec#92/206 |
| FCF | $1.09B | US#538/3,112 Sec#35/206 |
| Cash | $2.45B | US#352/3,112 Sec#18/206 |
| Current Ratio | 4.42x | US#546/3,112 Sec#52/206 |
| Net Debt/EBITDA | -1.23x | US#273/3,112 Sec#18/206 |
| Performance | ||
| 1Y Return | 11.98% | US#1,734/3,112 Sec#121/206 |
| 1M Return | -5.87% | US#2,318/3,112 Sec#153/206 |
| From 52W High | -7.75% | US#832/3,112 Sec#58/206 |
| 1Y MDD | -13.19% | US#200/3,112 Sec#3/206 |
| Trading | ||
| Volume | 3,072,939 shares | US#615/3,112 Sec#33/206 |
| Trading Value | $271M | US#403/3,112 Sec#32/206 |
| Per Share | ||
| EPS | $1.84 | US#1,332/3,112 Sec#71/206 |
| BPS | $17.81 | US#1,313/3,112 Sec#74/206 |
Company Info
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.